Navigation Links
High risk of acute mountain sickness on Mount Kilimanjaro
Date:10/6/2010

New Rochelle, NY, October 6, 2010 Climbers of high peaks such as Mount Kilimanjaro are at high risk for Acute Mountain Sickness (AMS). Trekkers should not ignore AMS warning signs, which can progress to more serious medical outcomes. Mountain climbers can best minimize their risk for altitude sickness by becoming acclimatized to increased altitudes before an ascent, according to a study in the current issue of High Altitude Medicine & Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/ham

The study, entitled "Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro," evaluated the incidence of AMS among trekkers of this popular climbing destination. Stewart Jackson, J. Kenneth Baillie, and colleagues from University of Edinburgh (Scotland) and Muhimbili University College of Health Science (Tanzania), compared the effects of three increasingly difficult and rapid ascent routes, the option of a single rest day during the climb, and use by a sub-group of climbers of prophylactic acetazolamide.

The authors reported a similar rate of AMS among climbers with or without prophylactic drug use. Furthermore, a mid-climb rest day did not affect the incidence of AMS. Only prior acclimatization to increased altitude offered a significant protective effect against AMS.

"This important article emphasizes the dangers of rapid ascent rates on a mountain that attracts thousands of visitors every year. Hopefully it will help to reduce the high frequency of high altitude diseases," says John B. West, MD, PhD, Editor-in-Chief of High Altitude Medicine & Biology and Professor of Medicine at the University of California, San Diego School of Medicine.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers
2. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
3. Drinking alcohol during pregnancy could lead to acute myeloid leukemia in children
4. Vicious circle offers new acute leukemia treatment target
5. Study shows pine bark naturally relieves symptoms of acute hemorrhoids
6. First-in-class treatment for acute leukemia
7. Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia
8. Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients
9. A miR boost enables acute leukemia cells to mature
10. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
11. When acute hepatitis develops into chronic hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High risk of acute mountain sickness on Mount Kilimanjaro
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: